272 related articles for article (PubMed ID: 24627109)
21. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.
Müller ML; Albin RL; Kotagal V; Koeppe RA; Scott PJ; Frey KA; Bohnen NI
Brain; 2013 Nov; 136(Pt 11):3282-9. PubMed ID: 24056537
[TBL] [Abstract][Full Text] [Related]
22. 6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
Fricke IB; Viel T; Worlitzer MM; Collmann FM; Vrachimis A; Faust A; Wachsmuth L; Faber C; Dollé F; Kuhlmann MT; Schäfers K; Hermann S; Schwamborn JC; Jacobs AH
Eur J Neurosci; 2016 May; 43(10):1352-65. PubMed ID: 26950181
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography molecular imaging of dopaminergic system in drug addiction.
Hou H; Tian M; Zhang H
Anat Rec (Hoboken); 2012 May; 295(5):722-33. PubMed ID: 22467195
[TBL] [Abstract][Full Text] [Related]
24. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.
Christopher L; Marras C; Duff-Canning S; Koshimori Y; Chen R; Boileau I; Segura B; Monchi O; Lang AE; Rusjan P; Houle S; Strafella AP
Brain; 2014 Feb; 137(Pt 2):565-75. PubMed ID: 24334314
[TBL] [Abstract][Full Text] [Related]
25. Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.
Branch SY; Chen C; Sharma R; Lechleiter JD; Li S; Beckstead MJ
J Neurosci; 2016 Apr; 36(14):4026-37. PubMed ID: 27053209
[TBL] [Abstract][Full Text] [Related]
26. Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.
Niu J; Zhong Y; Jin C; Cen P; Wang J; Cui C; Xue L; Cui X; Tian M; Zhang H
Neurosci Bull; 2024 Jun; 40(6):743-758. PubMed ID: 38483697
[TBL] [Abstract][Full Text] [Related]
27. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias.
Colloby SJ; McParland S; O'Brien JT; Attems J
Brain; 2012 Sep; 135(Pt 9):2798-808. PubMed ID: 22961551
[TBL] [Abstract][Full Text] [Related]
28. Aberrant plasticity and "learned" motor inhibition in Parkinson's disease.
Zhuang XX
Sheng Li Xue Bao; 2012 Oct; 64(5):543-9. PubMed ID: 23090495
[TBL] [Abstract][Full Text] [Related]
29. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
30. Dopaminergic function and progression of Parkinson's disease: PET findings.
Biju G; de la Fuente-Fernández R
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S38-40. PubMed ID: 20123555
[TBL] [Abstract][Full Text] [Related]
31. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
[TBL] [Abstract][Full Text] [Related]
32. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
[TBL] [Abstract][Full Text] [Related]
33. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
34. Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms.
Ballanger B; Beaudoin-Gobert M; Neumane S; Epinat J; Metereau E; Duperrier S; Broussolle E; Thobois S; Bonnefoi F; Tourvielle C; Lavenne F; Costes N; Lebars D; Zimmer L; Sgambato-Faure V; Tremblay L
J Neurosci; 2016 Feb; 36(5):1577-89. PubMed ID: 26843639
[TBL] [Abstract][Full Text] [Related]
35. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
36. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.
Kreitzer AC; Malenka RC
Nature; 2007 Feb; 445(7128):643-7. PubMed ID: 17287809
[TBL] [Abstract][Full Text] [Related]
37. What has PET told us about Parkinson's disease?
Aquilonius SM
Acta Neurol Scand Suppl; 1991; 136():37-9. PubMed ID: 1801535
[TBL] [Abstract][Full Text] [Related]
38. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease.
Pak K; Shin HK; Kim EJ; Lee JH; Lyoo CH; Son J; Lee MJ
Parkinsonism Relat Disord; 2018 Jun; 51():67-72. PubMed ID: 29510907
[TBL] [Abstract][Full Text] [Related]
39. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Thobois S; Guillouet S; Broussolle E
Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
[TBL] [Abstract][Full Text] [Related]
40. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
